ImPACT

Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial

Study Overview The research presented focuses on evaluating the efficacy and safety of a fixed-dose combination of daily doravirine (100

Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial Read Post »

Epidemiological trends and cross-country inequalities in the global burden of Alzheimer’s disease and other dementias in postmenopausal women from 1990 to 2021

Epidemiological trends Recent data illustrate a concerning rise in the prevalence and incidence of Alzheimer’s disease and other dementias, particularly

Epidemiological trends and cross-country inequalities in the global burden of Alzheimer’s disease and other dementias in postmenopausal women from 1990 to 2021 Read Post »

Scroll to Top